Adaptive BiotechnologiesADPT
About: Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
Employees: 619
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
6,904% more call options, than puts
Call options by funds: $1.89M | Put options by funds: $27K
100% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 2 (+1) [Q2]
67% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 27
52% more capital invested
Capital invested by funds: $1.14B [Q1] → $1.72B (+$586M) [Q2]
41% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 64
5% more funds holding
Funds holding: 226 [Q1] → 238 (+12) [Q2]
5.59% less ownership
Funds ownership: 102.93% [Q1] → 97.34% (-5.59%) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
JP Morgan Rachel Vatnsdal | 10%upside $14 | Overweight Maintained | 6 Aug 2025 |
TD Cowen Dan Brennan | 18%upside $15 | Buy Maintained | 6 Aug 2025 |
Piper Sandler David Westenberg | 18%upside $15 | Overweight Maintained | 6 Aug 2025 |
Craig-Hallum John Wilkin | 18%upside $15 | Buy Initiated | 18 Jun 2025 |
Financial journalist opinion
Based on 10 articles about ADPT published over the past 30 days
